Regeneron Pharmaceuticals
This study will test a Regeneron study drug called ALN-CIDEB to find out whether it may help treat a liver disease called metabolic dysfunction-associated steatohepatitis (MASH). MASH is more advanced stage of a broader liver disease, MASLD. MASLD is a liver condition caused by too much fat building up in the liver. This can lead to liver scarring and inflammation and can reduce the liver's ability to keep the body healthy. Cell death-inducing DFFA-like effector B (CIDEB) is a protein made by liver cells that helps the liver to store fat. The study is looking at: * What side effects ALN-CIDEB might cause * How well ALN-CIDEB works to change liver fat, liver injury, and liver scarring * How ALN-CIDEB could affect the body and the liver, which can help researchers understand why ALN-CIDEB works better for some people than others
Key Inclusion Criteria: 1. Has a clinical diagnosis of MASLD, as defined in the protocol 2. Has a liver stiffness measurement between 6 and 20 kilopascals (kPa), as measured by a FibroScan® scan during screening or within approximately 3 months of screening, as defined in the protocol Key Exclusion Criteria: 1. Has a known chronic liver disease other than MASLD, as determined by the investigator, as defined in the protocol 2. Has prior or current suspected or known drug-induced liver injury within approximately 1 year prior to screening 3. Has a history of liver transplantation, current pla…
Administered per the protocol
Administered per the protocol
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.